Since VEGF-A was demonstrated to be overexpressed in prostate cancer and associated with poor prognosis and metastasis, most anti-angiogenic clinical studies in prostate cancer have targeted VEGF-A. This evidence concerns the gene VEGFA and Familial prostate cancer.